NASDAQ:CMND Clearmind Medicine Q4 2024 Earnings Results & Report $6.19 -0.04 (-0.64%) As of 02:27 PM Eastern This is a fair market value price provided by Massive. Learn more. Clearmind Medicine reported Q4 2024 earnings on January 22, 2025. The company reported EPS of -$352.00. Research:ProfileEarnings History Earnings Announcement Details QuarterQ4 2024Report DateJanuary 22, 2025TimeAfter Market ClosesConference Call DateJanuary 21, 2025Conference Call6:00 PM ET Clearmind Medicine EPS ResultsActual EPS-$352.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AClearmind Medicine Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesReportAnnual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsReportAnnual Report(20-F) Clearmind Medicine Q4 2024 Earnings FAQ Did Clearmind Medicine beat earnings estimates for Q4 2024? Clearmind Medicine (NASDAQ:CMND) reported earnings of -$352.00 per share for Q4 2024. The report was announced on Wednesday, January 22, 2025. Clearmind Medicine Earnings HeadlinesClearmind Subsidiary Launches Wireless EV-Charging Platform For Autonomous FleetsOctober 13 at 5:10 AM | rttnews.comClearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous FleetsOctober 13 at 5:10 AM | markets.businessinsider.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 14 at 1:00 AM | Profits Run (Ad)Clearmind Gains Japan Patent Coverage For 3-MMC And PEA CombinationOctober 8, 2026 | rttnews.comClearmind Medicine Announces Japanese Patent Application Publication for 3-MMC-Based Dyskinesia Treatment, Including PEA CombinationsOctober 8, 2026 | quiverquant.comQClearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement DisorderOctober 8, 2026 | globenewswire.comSee More Clearmind Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Clearmind Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearmind Medicine and other key companies, straight to your email. Email Address About Clearmind MedicineClearmind Medicine (NASDAQ:CMND) (NASDAQ: CMND) is a clinical-stage biotechnology company developing psychedelic-derived therapeutics for underserved health conditions. The company’s research focuses on creating proprietary compounds designed to address disorders involving addictive and compulsive behaviors. Clearmind’s lead research program centers on MEAI, a proprietary psychedelic molecule being evaluated for potential use in alcohol use disorder and binge-related behaviors. The company has also investigated additional applications for its compounds, including treatments for obesity and other conditions associated with abnormal consumption patterns. Clearmind advances its programs through preclinical research, intellectual-property development and clinical testing, with the goal of establishing new pharmaceutical treatments rather than providing psychedelic services directly. The company is headquartered in Israel and operates as a biotechnology developer serving the global pharmaceutical and healthcare markets.View Clearmind Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
